In 2023, sales of antiarrhythmic medicines in Canada were valued at 22.4 million Canadian dollars. From the forecast for 2024 to 2028, the sales are projected to decrease steadily. The year-on-year decline from 2024 to 2025 is 3.7%, and a 3.3% drop for the following year. By 2027 and 2028, the annual decline slightly varies by 3.5% each year. Overall, the compound annual growth rate (CAGR) over the five-year forecast period is -3.5%. This suggests an overall downward trend in sales volume.
Future trends to watch for include potential regulatory changes impacting drug prices, shifts in medical guidelines influencing treatment practices, and advancements in alternative therapies that could affect market demand. Monitoring these trends and their implications for antiarrhythmic medicines will be crucial for forecasting beyond 2028.
